sellModerate cluster of 510b5-1 plan
Bruce Booth sold $44M of KYMR
director at Kymera Therapeutics, Inc.. 398,765 shares at an average of $110.31, traded Jun 23, 2026, filed Jun 25, 2026.
Warning score
40Value
$44M
398,765 shares
Holdings after
564,668
-12% from before
From 52-week low
+161%
low $37.68, close $98.25
From 52-week high
-1%
high $99.45, as of Jun 23, 2026
Score components
- +15RoleDirector
- +25Trade size$44.0M at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
KYMROct 12, 2026 · close 112.08
Since filing Jun 25, 2026: -3.8%SPY +6.2% · excess -10.0%
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001451612-26-000015, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 23, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,235 | $99.98 | $123k | 3,461,521 | Jun 25, 2026 |
| Jun 23, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -173 | $99.98 | $17k | 613,589 | Jun 25, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -103,688 | $100.42 | $10M | 3,357,833 | Jun 25, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -14,513 | $100.42 | $1.5M | 599,076 | Jun 25, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -14,490 | $101.14 | $1.5M | 3,343,343 | Jun 25, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,029 | $101.14 | $205k | 597,047 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -9,994 | $107.30 | $1.1M | 3,333,349 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -159 | $108.02 | $17k | 3,333,190 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -14,351 | $108.83 | $1.6M | 3,318,839 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,915 | $110.30 | $211k | 3,316,924 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -614 | $110.79 | $68k | 3,316,310 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -719 | $111.89 | $80k | 3,315,591 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -10,215 | $113.70 | $1.2M | 3,305,376 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -9,229 | $114.65 | $1.1M | 3,296,147 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -58,205 | $115.57 | $6.7M | 3,237,942 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -81,500 | $116.53 | $9.5M | 3,156,442 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -24,268 | $117.50 | $2.9M | 3,132,174 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -19,089 | $118.60 | $2.3M | 3,113,085 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,399 | $107.30 | $150k | 595,648 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -23 | $108.02 | $2,484 | 595,625 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,011 | $108.83 | $219k | 593,614 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -265 | $110.30 | $29k | 593,349 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -86 | $110.79 | $9,528 | 593,263 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -100 | $111.89 | $11k | 593,163 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,437 | $113.70 | $163k | 591,726 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,289 | $114.65 | $148k | 590,437 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -8,389 | $115.57 | $970k | 582,048 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -11,375 | $116.53 | $1.3M | 570,673 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,359 | $117.50 | $395k | 567,314 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,646 | $118.60 | $314k | 564,668 | Jun 25, 2026 |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 41Moderate | KYMRsell Kymera Therapeutics, Inc. | Brian Adams Chief Legal Officer | $744k 6,371 shares | -11% | |
| 30Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $6.0M 50,000 shares | -7% | |
| 26Weak | Kymera Therapeutics, Inc. | Noah Goodman Chief Business Officer | $387k 3,389 shares | -7% | |
| 32Weak | Kymera Therapeutics, Inc. | Bruce N. Jacobs Chief Financial Officer | $8.9M 77,109 shares | -24% | |
| 35Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $9.2M 80,000 shares | -11% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $8.3M 76,650 shares | -3% | |
| 40Moderate | Kymera Therapeutics, Inc. | Bruce Booth director | $56M 513,245 shares | -18% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $3.4M 31,283 shares | -1% | |
| 75Notable | Kymera Therapeutics, Inc. | Bvf Partners L P/il director, other | $174M 1,630,658 shares | -58% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.